Page Biopharmaceuticals-B (02565): CR059 related research summary has been accepted and selected as the latest breakthrough abstract at the American Diabetes Association's 2026 Scientific Sessions.

Peg BioPharma-B (02565) announced that the research summary of the innovative candidate product CR059, independently developed by the group, has been accepted and selected as a Late Breaking Abstract at the American Diabetes Association (ADA) 2026 Scientific Sessions. It will be presented in poster form. The research summary is titled "CR059, a Once-Monthly circRNA-Encoded GLP-1 Analogue, Demonstrates Durable Glycemic Control in T2D Rhesus Monkeys." CR059 is an innovative candidate product independently developed by the group. According to the research results, CR059 has shown significant weight loss effects, outstanding blood sugar reduction performance, and long-term expression characteristics, indicating the development potential as a long-acting metabolic disease treatment. The abstract also shows that CR059 is based on circRNA-LNP technology platform and has the potential for monthly dosing, even extending to quarterly dosing, supporting sustained expression and long-term metabolic control. The ADA Scientific Sessions are one of the internationally influential academic conferences in the field of diabetes and metabolic diseases. The board believes that the acceptance and selection of the CR059-related research summary as a Late Breaking Abstract reflect the international academic community's attention to the group's latest progress in innovative research and development in the field of metabolic diseases. This will help enhance the international academic influence of the CR059 project and increase market recognition of the group's innovative research and development capabilities and technology platform value. According to the conference schedule, the above research summary will be presented in poster form during the ADA 2026 Scientific Sessions.